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Abstract
We designed and engineered mitochondrially targeted obligate
heterodimeric zinc finger nucleases (mtZFNs) for site-specific elim-
ination of pathogenic human mitochondrial DNA (mtDNA). We
used mtZFNs to target and cleave mtDNA harbouring the
m.8993T>G point mutation associated with neuropathy, ataxia,
retinitis pigmentosa (NARP) and the common deletion (CD), a
4977-bp repeat-flanked deletion associated with adult-onset
chronic progressive external ophthalmoplegia and, less frequently,
Kearns-Sayre and Pearsons marrow pancreas syndromes. Expres-
sion of mtZFNs led to a reduction in mutant mtDNA haplotype
load, and subsequent repopulation of wild-type mtDNA restored
mitochondrial respiratory function in a CD cybrid cell model. This
study constitutes proof-of-principle that, through heteroplasmy
manipulation, delivery of site-specific nuclease activity to mito-
chondria can alleviate a severe biochemical phenotype in primary
mitochondrial disease arising from deleted mtDNA species.
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Introduction
Human mitochondria have their own small, circular genome (mtDNA)
that encodes essential subunits of the oxidative phosphorylation
(OXPHOS) apparatus. Defects of the mitochondrial genome produce a
variety of genetic disorders with diverse clinical manifestations, for
which current therapy options are limited to management treatments
(Vafai & Mootha, 2012). Population-based studies of primary mtDNA-
mediated disease report that average prevalence is 9.2/100,000 (Schae-
fer et al, 2008) and deletions of mtDNA are a common cause of sporadic
disease, with single mtDNA deletions accounting for one-third of
adults presenting with mitochondrial disease (Chinnery et al, 2000).
Delivery and selection of mtDNA in mitochondria in a heritable
manner is yet to be achieved, so alternative approaches to genetic ther-
apy of primary mitochondrial diseases are being sought. One of these
approaches is based on pathogenic mtDNA mutations being generally
heteroplasmic, with observable pathology only present when the ratio
of mutated mtDNA exceeds a certain threshold. The selective elimina-
tion of mutated mtDNA allows a cell to repopulate with wild-type
mtDNA molecules by a yet uncharacterized mechanism of mtDNA
copy number maintenance (Carling et al, 2011), alleviating the defec-
tive mitochondrial function that underlies mtDNA diseases (Taylor
et al, 1997). Selective degradation of mtDNA bearing point mutations
has been achieved by introducing DNA double-strand (ds) breaks
using mitochondrially targeted restriction endonucleases (mtRE) in
cellular models of disease (Tanaka et al, 2002; Alexeyev et al, 2008).
Also, in vivo expression of mtRE efficiently shifted heteroplasmy
towards desired mtDNA variants and was reasonably safe in mouse
models (Bayona-Bafaluy et al, 2005; Bacman et al, 2010, 2012). How-
ever, there is no appropriate RE for the vast majority of pathological
mutations, limiting their usefulness. Furthermore, mtDNA deletions,
where a large section of the mitochondrial genome is missing, present
a further targeting challenge. Deletions of mtDNA are invariably het-
eroplasmic and tend to have a lower pathogenicity threshold (~60%)
than point mutations. Typically, the same mtDNA deletion is present
in all cells of an affected tissue and many are flanked by short direct
repeats. This latter feature renders mtDNA deletions impossible to tar-
get with REs as the deletion site will retain one direct repeat, and is
therefore indistinguishable from wild-type mtDNA.
Engineered zinc finger nucleases (ZFNs) are chimeric enzymes uti-
lizing the modular Cys2His2 zinc finger DNA-binding moiety conju-
gated to the C-terminal catalytic subunit of the type II restriction
enzyme FokI (Kim et al, 1996; Smith et al, 2000). By arranging zinc
finger modules appropriately, virtually any DNA sequence can be tar-
geted for nucleolytic cleavage by ZFN. A conventional ZFN strategy
consists of targeting two ZFN monomers to bind adjacent sites on
complementary DNA strands spanning the target sequence, thus
1 Medical Research Council, Mitochondrial Biology Unit, Cambridge, UK
2 Sangamo BioSciences Inc., Richmond, CA, USA
*Corresponding author. Tel: +44 1223 252750; Fax: +44 1223 252715; E-mail: michal.minczuk@mrc-mbu.cam.ac.uk
EMBO Molecular Medicine Vol 6 | No 4 | 2014 ª 2014 The Authors.This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
458
allowing dimerization of the FokI nuclease domain, required to cleave
double-stranded DNA. ZFN technology has been used routinely to
engineer nuclear genomes in order to add, correct or disrupt genes
(Papworth et al, 2006; Pearson, 2008) and is currently available com-
mercially and via various protocols for in-house manufacture (Carroll
et al, 2006; Maeder et al, 2008; Kim et al, 2011; Sander et al, 2011).
In this work, we have expanded the use of mtZFNs through sig-
nificant design enhancements that permit targeting of pathogenic
mitochondrial genomes in cybrid cells. When targeted to pathogenic
mtDNA harbouring a point mutation or large-scale deletion, mtZFN
expression produces a heteroplasmy shift towards wild-type mtDNA
through selective degradation of mutant mtDNA. Moreover, a
decrease in the mutant mtDNA load results in phenotypic rescue of
the severe bioenergetic dysfunction associated with high levels of
partially deleted mtDNA. Thus, we provide a robust method for site-
specific editing of mtDNA in patient-derived cybrid cells, with future
therapeutic potential.
Results
Improved design of mtZFNs
Our earlier research found that efficient targeting of ZFNs to
human mitochondria requires a mitochondrial targeting signal
(MTS) as well as nuclear localization signal (NES) (Minczuk et al,
2006). The previously reported architecture of mtZFN monomers
(Fig 1A) (Minczuk et al, 2008; Minczuk, 2010) was adapted by
placing MTS-epitope tag-NES at the N-terminus. In contrast to pre-
vious designs, the Myc tag of one of the monomers was replaced
with a FLAG tag. We also incorporated modified FokI domains
that cleave DNA only when paired as a heterodimer (ELD/KKR).
These FokI variants exhibit efficiency comparable to the wild-type
architecture, but with a > 40-fold reduction in homodimer activity
(Miller et al, 2007; Szczepek et al, 2007; Doyon et al, 2011)
(Fig 1B).
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Figure 1. Improved design and localization of mtZFNs.
A Schematic structure of previous mtZFN architecture. Mitochondrial targeting is facilitated by a 49-amino acid-long MTS from subunit F1b of human mitochondrial
ATP synthase. To ensure that the MTS cleavage site is upstream of the epitope tag, its length was adjusted using proteomic data (Carroll et al, 2009) that identified
the N-terminus of the mature subunit at Ala48. NES, nuclear export signal; ZFP, zinc finger peptide; M, Myc tag; HA, haemagglutinin tag.
B Schematic of the novel obligatory heterodimeric mtZFN monomers. “+” and “”, ELD and KKR modified FokI domain, respectively (Doyon et al, 2011); F, FLAG tag;
AA, two-alanine linker; GS, glycine-serine linker (Kim et al, 1996).
C The intracellular localization of mtZFNs by immunofluorescence. mtZFN(+) or mtZFN() was transiently expressed in HOS 143B cells. Cell nuclei were stained with
DAPI (blue, 1 and 5). mtZFN(+) and mtZFN() were detected by anti-HA and anti-FLAG antibodies, respectively, and visualized by Alexa Fluor 594-conjugated
secondary antibodies (red, 2 and 6). Mitochondria were detected with anti-TOM20/Alexa Fluor 488 antibodies (green, 3 and 7). Co-localization appears yellow on
digitally merged images (4 and 8). Scale bars: 10 lm. R8-4 and R13-2 mtZFNs were used in this example (Supplementary Table S2).
D Location of mtZFNs in subcellular fractions. HOS 143B cells stably transfected with mtZFNs were fractionated into cell debris/nuclei (D, lane 2), cytosol (C, lane 3)
and mitochondria (lanes 4–5). The mitochondrial fraction was treated with 25 lg/ml proteinase K (lane 5). T, total cell lysate. The fractions were analysed by
western blotting with anti-HA [mtZFN(+)] and anti-FLAG [mtZFN()]. The following marker proteins were used: mtSSB1 (mitochondrial matrix), TOM22
(mitochondrial outer membrane), b-actin (cytosol) and histone H4 (nucleus). p indicates mtZFN precursor (still containing MTS), and m indicates the mature form. fl
indicates TOM22 of full length; tr indicates proteinase K-truncated TOM22. R8-4 and R13-2 were used in this example.
Source data are available for this figure.
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In order to experimentally test whether mtZFNs of novel archi-
tecture are readily imported into mitochondria, we studied their
cellular localization upon transient expression in human osteosar-
coma (HOS) 143B cells. Immunofluorescence analysis revealed that
mtZFNs co-localize with mitochondria and there is no detectable
mtZFN-specific signal from the nucleus (Fig 1C). Further, cell frac-
tionation experiments confirmed the mitochondrial localization of
mtZFNs (Fig 1D). This experiment also showed that the MTS is
cleaved off from precursor mtZFN proteins, although incompletely;
this phenomenon is often observed, even for endogenous mitochon-
drial proteins expressed at a high level (Maniura-Weber et al, 2004).
The matured mtZFN form (Fig 1D, “m”) was resistant to proteinase
K treatment, consistent with mitochondrial matrix import. In similar
conditions, the outer membrane protein TOM22 was truncated by
proteinase K (Fig 1D). These results are consistent with mitochon-
drial localization of this novel obligatory heterodimeric mtZFN
architecture in human cells.
Testing the improved mtZFN design by selective degradation of
m.8993T>G NARP point mutation
To test the efficacy of our modified mtZFN design, we used previ-
ously assembled and optimized zinc finger peptides (ZFPs) with
reported specificity to the m.8993T>G substitution (Minczuk et al,
2008), which is associated with two mitochondrial diseases: neuro-
genic muscle weakness, ataxia and retinitis pigmentosa (NARP) and
maternally inherited Leigh syndrome (MILS) (Holt et al, 1990).
According to our strategy (Fig 2A), a mutation-specific mtZFN
monomer [Fig 2A, NARPd(+)] and a mtZFN monomer binding to
wild-type sequence upstream [Fig 2A, COMPa()] would dimerize
only at the mutation site and introduce DNA ds breaks, which are
inhibitory to mtDNA propagation.
We expressed NARPd(+) and COMPa() in cybrid cells harbour-
ing 93% m.8993T>G mtDNA and selected a bulk population of cells
expressing both constructs (Fig 2B). Simultaneous expression of
NARPd(+) and COMPa() for 18 days, as assessed by western blot-
ting, resulted in selective degradation of the m.8993T>G mtDNA
molecules, which was accompanied by a shift in heteroplasmy of
the cybrids from ~7% wild-type to ~17% wild-type, as assessed by
RFLP (Fig 2C and D, Supplementary Fig 1). Importantly, NARPd(+)/
COMPa() rescued heteroplasmy against the natural tendency of
the m.8993T>G cybrids cells to select the mutant haplotype over
time; in the course of the experiment, mock-transfected cells and
cells expressing individual mtZFN monomers demonstrated a het-
eroplasmy shift from ~7% to ~3% of wild-type mtDNA (Fig 2D).
Expression of NARPd(+) and/or COMPa() did not have any
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Figure 2. Targeting m.8993T>G with mtZFNs.
A Schematic of targeting mtDNA point mutations by mtZFNs. Red box, the binding site for the m.8993T > G-specific mtZFN monomer (NARPd); Blue box, binding site
for the companion mtZFN on the opposite strand (COMPa)
B Western blotting of ~93% m.8993T > G cybrid cells transfected with NARPd and/or COMPa and vector controls. b-Actin, loading control.
C RFLP analysis of last cycle hot PCR products (mtDNA nt positions 8339–9334) amplified from total DNA samples of ~93% m.8993T > G cybrid cells transfected with
vectors, NARPd and/or COMPa. Wild-type cells and 99% m.8993T > G cybrids were used as controls.
D Results of RFLP analysis as per (C) from three independent transfections. P value according to two-tailed Student’s t-test.
Source data are available for this figure.
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significant effect on mtDNA copy number (Supplementary Fig S2) or
cell viability, as informed by co-transfecting equal numbers of cells
with mtZFN monomers and fluorescent markers, followed by deter-
mining the percentage of marker-positive cells with a flow cytome-
ter (Supplementary Table S1) (Minczuk et al, 2008).
Next, we studied the effects of mtZFN expression on mtDNA rep-
lication using two-dimensional agarose gel electrophoresis
(2D-AGE). One specific issue that this technique can address is
whether or not binding of an individual catalytically inactive zinc
finger monomer could result in steric hindrance of mtDNA replica-
tion, producing stalled replication forks. To address this, we
expressed the COMPa() mtZFN, which binds wild-type mtDNA
sequence, in wild-type HOS 143B cells. The presence of COMPa()
in the mitochondrial matrix did not produce any appreciable effect
on mtDNA replication intermediates in a 2D-AGE analysis (Supple-
mentary Fig 3). This is consistent with mtZFN expression-linked
heteroplasmy shifts being attributable to nucleolytic cleavage, rather
than replication block.
Eliminating mtDNA “common deletion” by mtZFNs
Next, we addressed the feasibility of targeting pathogenic large-scale
mtDNA deletions in a cybrid cell model. We selected the most fre-
quently occurring large-scale mtDNA deletion of 4977 bp, the
so-called common deletion (CD), as the test sequence. This deletion
spans a region between two 13-bp direct repeats (nucleotide posi-
tions 8470–8482 and 13,447–13,459), containing several transfer
RNA and structural genes of the OXPHOS apparatus (Fig 3A). CD
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Figure 3. Targeting mtDNA “common deletion” (CD) with mtZFNs.
A Wild-type mtDNA is not cleaved as mtZFN R8-n(+) and R13-n() monomers (where n is a specific construct number) bind several kilobases apart preventing
dimerization of the FokI domain. Red and blue boxes, the binding sites for mtZFN monomers on either side of the CD (Supplementary Table 2); Black boxes, the 13-
bp direct repeats.
B mtDNA harbouring CD is cleaved as adjacent binding of the mtZFN R8-n(+) and R13-n() monomers results in FokI dimerization.
C Western blotting of bulk populations of H39 CD cybrid cells transfected with the R8-4(+) and/or R13-1() constructs and vector controls. b-Actin, loading control.
D Southern blot analysis of total DNA from wild-type (WT), mock- or mtZFN-transfected cells digested with BamHI and probed with a radioactive mtDNA-specific
probe (region: 14986–15607), 18S rDNA probe is used as a loading control.
E Analysis of mtDNA heteroplasmy in clones expressing CD-specific mtZFNs as indicated. % wild-type mtDNA was measured by Southern blotting. Grey dots indicate
individual clones; coloured bars indicate the average value for each mtZFN pair. P values calculated in two-tailed Student’s t-test.
Source data are available online for this figure.
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often manifests in adult-onset chronic progressive external ophthal-
moplegia (CPEO) associated with ptosis and restriction of eye move-
ments and, less frequently, with Kearns-Sayre and Pearson’s
marrow pancreas syndromes (Grady et al, 2013). According to our
strategy, wild-type mtDNA is spared as binding sites for the mtZFN
monomers are several kilobases apart, preventing dimerization of
the nuclease domains (Fig 3A). However, in the CD mtDNA, mtZFN
monomers bind adjacently at the CD junction (Fig 3B). This allows
dimerization of FokI domains and introduction of DNA ds breaks,
which are inhibitory to mtDNA propagation (Fig 3B).
We assembled several ZFN monomers to bind DNA targets
downstream of the 8470–8482 repeat (Fig 3, R8-n(+), n = construct
number) and a further set of ZFNs targeting a site upstream of the
13,447–13,459 repeat (Fig 3, R13-n(), n = construct number)
(Supplementary Table S2, Supplementary Notes S1, S2). The R8-n(+)
and R13-n() design was then tested in vitro for specificity to the
CD break point site (Supplementary Fig 4). To this end, we synthe-
sized ZFNs in an in vitro transcription and translation (IVTT) sys-
tem. We incubated IVTT-produced R8-n and R13-n monomers,
individually or in pairs, with DNA substrates corresponding to the
joining site resulting from CD, or with DNA probes containing
mtDNA wild-type sequence proximal to the 8470–8482 or 13,447–
13,459 direct repeats (Supplementary Note 3) (Minczuk et al, 2010).
This analysis identified several R8-n(+)/R13-n() pairs that cleaved
the CD-specific DNA, while sparing the wild-type substrates; these
were selected for further analysis (Supplementary Fig S4).
Next, we tested whether these selected mtZFNs were effective in
degrading CD mtDNA in heteroplasmic cells (Porteous et al, 1998).
To determine this, we transfected the R8-4(+) and R13-1() mtZFN
variants individually or concurrently into HOS H39 cells (Porteous
et al, 1998), which harbour on average ~85% CD mtDNA, and
selected a bulk population of cells expressing mtZFNs (Fig 3C). We
analysed mtDNA heteroplasmy in transfected H39 cells using South-
ern blotting, allowing the detection of expected mtDNA haplotypes,
as well as potential, undesired recombined mtDNA species (Bacman
et al, 2009) (Fig 3D). This analysis showed that simultaneous
expression of both the R8-4(+) and R13-1() mtZFNs for 18 days
led to efficient degradation of CD mtDNA, shifting the proportion of
wild-type mtDNA from ~15% to ~76% (Fig 3D). Mock-transfected
cells or cells expressing high levels of either R8-4(+) or R13-1()
individually did not show any appreciable changes in heteroplasmy
levels and no recombined mtDNA species were detected in any con-
ditions (Fig 3D). The presence of R8-4(+) and/or R13-1() mono-
mers did not have any significant effect on mtDNA copy number
(Supplementary Fig S5). These results demonstrate that CD-specific
mtZFNs are capable of reducing pathogenic mtDNA deletion content
in a cybrid cell model.
In order to provide further evidence for selective degradation of
pathogenic rearranged mtDNA by mtZFNs, we retested the R8-4(+)/
R13-1() combination and two other CD-specific mtZFN pairs
(Supplementary Fig S5) in clonal H39 cell lines transfected with
appropriate DNA constructs. There were two key reasons for testing
the mtZFNs in clonal cell lines. First, we observed that the hetero-
plasmy shift leading to dominance of wild-type mtDNA was accom-
panied by a considerable growth advantage (Supplementary Fig S6),
so it was conceivable that the bulk population will over-represent
cells with higher levels of wild-type mtDNA rather than demonstrate
the true relationship between wild-type and CD mtDNA in
individual cells. Secondly, homogenous populations of cells were
required for an extracellular flux analysis of OXPHOS function (see
below). In this experiment, HOS H39 cells were transfected with
the following combination of mtZFN constructs: R8-4(+)/R13-1(),
R8-4(+)/R13-2() and R8-13(+)/R13-1(). Additionally, R8-4(+),
R13-1() and R13-2() were tested individually. When representa-
tive clones were analysed to assess wild-type/CD mtDNA ratio by
Southern blotting, all mtZFN pairs tested were capable of eliminat-
ing the pathogenic mtDNA deletion (Fig 3E, Supplementary Fig S5).
However, on average, they exhibited lower levels of wild-type
mtDNA as compared with the initial bulk population. Of note, a
clone that demonstrated ~70% wild-type mtDNA was also observed
in this experiment; however, it was removed from Fig 3E after
statistical analysis as it lay >10 standard deviations from the mean.
Rescue of mtDNA “common deletion”-associated mitochondrial
defect by mtZFNs
Next, we set out to determine whether mtZFN-dependent shifts in
heteroplasmy from CD to wild-type mtDNA were associated with
rescue of mitochondrial respiratory function. The region of CD
spans seven genes coding for structural subunits of complexes I, IV
and V and also several transfer RNA (Fig 3A). Consequently, high
levels of CD mtDNA are associated with a generalized OXPHOS
defect. We measured oxygen consumption rate (OCR) in controls
and clonal H39 cells expressing CD-specific mtZFNs in an extracellu-
lar flux analysis. OCR of control H39 cells expressing single mtZFN
monomers [R13-1() or R13-2()] with high levels of CD was virtu-
ally indistinguishable from that of mtDNA-less (Rho0) cells (Fig 4A,
blue and black traces, respectively), consistent with data published
previously (Porteous et al, 1998). The specific shift in mtDNA het-
eroplasmy from CD towards wild-type produced by expression of
R8-4(+)/R13-2() or R8-13(+)/R13-1() mtZFNs (Fig 4B) resulted
in rescue of OCR (Fig 4A, green traces). Furthermore, degradation
of CD mtDNA in clonal H39 HOS cell lines expressing mtZFN pairs
resulted in increased abundance of respiratory complex subunits as
compared to control H39 or Rho0 cells (Fig 4C). These data confirm
that the defect of mitochondrial gene expression and OXPHOS func-
tion in H39 HOS cells displaying high levels of CD mtDNA is cor-
rected by mtZFNs specifically degrading CD genomes, allowing
wild-type mtDNA to repopulate the cell.
Discussion
This work is concerned with solving the longstanding problem of
how to manipulate the human mitochondrial genome and, eventu-
ally, correct point mutations and deletions in mtDNA that are asso-
ciated with human pathologies. Currently, these pathologies are
untreatable and difficult for clinicians to manage; frequently, they
lead to severe dysfunction in early childhood and premature death;
thus, finding a solution is a major priority (Pfeffer et al, 2013). Here,
we describe a significant step towards achieving this goal using
engineered zinc finger nucleases selected to target and cleave prede-
termined loci in mtDNA.
We report a redesigned, conventional dimeric mtZFN architec-
ture to provide a safe and universal approach for genetic manipula-
tion of the mitochondrial genome. Our previous designs for mtZFN
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monomers were inefficient when targeting mtDNA point mutations
in living cells (Minczuk et al, 2008), despite exhibiting high specific-
ity in vitro (Minczuk, 2010). This prompted us to target a specific
point mutant sequence in human mtDNA with a single-chain ZFN
that carries two cleavage domains linked to the same protein (Minc-
zuk et al, 2008). The strategy of linking two cleavage domains,
although successful in targeting mtDNA point mutations, cannot be
used to target the break points of many mtDNA deletions (see
Introduction). Another limitation of single-chain ZFNs is that the
enzyme may be constitutively active as a nuclease, partially com-
promising its safe use. An attractive feature of the more conven-
tional dimeric ZFN scheme is that the cleavage reagent is assembled
at the target and is otherwise inactive. This encouraged us to revisit
the initial approach and improve the dimeric mtZFN architecture.
Our earlier designs for mtZFN monomers, in addition to the
N-terminal MTS, contained epitope tags and the NES sequence at the
C-terminus following the wild-type FokI domain (Minczuk, 2010;
Minczuk et al, 2010) (Fig 1A). The incorporation of NES, in addi-
tion to the MTS, has been shown to be necessary to circumvent the
issue of undesired nuclear localization of mtZFN and other proteins
(Minczuk et al, 2006; Suzuki et al, 2010). Other studies have shown
that this was likely attributable to an internal nuclear localization
signal (NLS) that overlaps residues important for contacting DNA in
zinc finger proteins (Matheny et al, 1994; Fernandez-Martinez et al,
2003). The probable key weaknesses of the previous mtZFN archi-
tecture, limiting its safety and/or efficacy, were: (i) potential inter-
ference of extra domains (HA/Myc and NES) with FokI at the
C-terminus, (ii) destabilization of mtZFNs by the Myc tag, as observed
for other mitochondrially targeted proteins studied in our laboratory,
(iii) tendency of wild-type FokI to form cleavage-competent homodi-
mers, resulting in off-target cleavage events and subsequent
depletion of mtDNA copy number in conditions where only one
mtZFN monomer is present in mitochondria (Minczuk et al, 2008).
Having addressed these issues (Fig 1b), our novel obligatory
heterodimeric mtZFN architecture has been demonstrated to localize
to mitochondria (Fig 1C and D) and selectively eliminate pathogenic
mtDNA bearing the m.8993T>G point mutation (Fig 2). Importantly,
this effect was shown not to be mediated by mtDNA replication
stalling and subsequent replicative advantage (Supplementary Fig
S3). Compared to the previously reported single-chain ZFN targeting
m.8993T>G, our current design is superior in shifting heteroplasmy
while using the same, mutant-specific DNA-binding zinc finger pep-
tide (NARPd). Long-term expression of the m.8993T>G-specific single-
chain ZFN resulted in ~twofold increase in wild-type mtDNA
content as compared to the mock control (Minczuk et al, 2008). The
dimeric mtZFN targeting the same mutation in this study produced
~fivefold more wild-type mtDNA relative to the controls (Fig 2).
Importantly, the improved mtZFN monomers did not exert any
effect on mtDNA when expressed individually (Fig 2).
In order to expand the use of mtZFNs for mtDNA heteroplasmy
manipulation, beyond pathogenic point mutations, we targeted the
most frequently occurring disease-associated large-scale mtDNA
deletion, the “common deletion” (CD) (Fig 3). Expression of several
combinations of CD-specific mtZFNs led to a reduction in mutant
mtDNA haplotype load below the pathogenicity threshold. Subse-
quent repopulation of wild-type mtDNA produced a profound recov-
ery of OXPHOS function in treated cells (Fig 4). With several
combinations of mtZFNs capable of specifically degrading targeted
mtDNA variants, these data predict that the mtZFN approach could
be advantageous to patients with primary mitochondrial diseases
and may constitute a feasible genetic therapy approach in the future.
The highly efficient shift in heteroplasmy from mutant to wild-
type for the CD cell line contrasted with the shift observed in the
m.8993T>G cells. There are two plausible reasons for this: (i) there
is a far lower starting quantity of wild-type mtDNA in the
m.8993T>G cell line; therefore, the rapid, initial elimination of
0
10
20
30
40
50
60
70
80
0 20 40 60 80 100 120 140 160 180 
WT
Rho0O
C
R
 [f
m
ol
es
/m
in
]
2-DG FCCPoligomycin rotenone
time [min]
R8-4(+)
R13-2(-)
R8-13(+)
R13-1(-)
R13-1(-)
vector
R13-2(-)
vector
WT R
ho
0
R
8-
4(
+)
R
13
-2
(-
)
R
8-
13
(+
)
R
13
-1
(-
)
R
13
-1
(-
)
ve
ct
or
R
13
-2
(-
)
ve
ct
or
100 N/A 7 5 42 40
10 kb - 
16.5 kb - 
8 kb - 
 SDHB (cII)
 ATP5 (cV)
 NDUFB8 (cI)
 CO2 (cIV)
- WT
- CD
% WT
- 18S rDNA
 UQCRC2  (cIII)
WTWT CD R
ho
0
R
8-
4(
+)
R
13
-2
(-
)
R
8-
13
(+
)
R
13
-1
(-
)
R
13
-1
(-
)
ve
ct
or
R
13
-2
(-
)
ve
ct
or Mitoprep
Coomassie
gel stain
A
B
C
Figure 4. Recovery of OXPHOS function upon elimination of CD mtDNA
by mtZFNs.
A Oxygen consumption rate (OCR) measured in quadruplicate for wild-type
(WT, white), Rho0 (black) and clonal cells expressing CD-specific mtZFNs
from the same transfection/selection experiment.
B Southern blot analysis of total DNA from wild-type (WT), Rho0 and mock-
or mtZFN-transfected clonal cells used in OCR analysis.
C Western blot analysis of steady-state levels of OXPHOS subunits in clonal
cell lines as per (A) and (B). Mitochondrial preparations of WT and CD cells
(Mitoprep) were also analysed in this experiment. Coomassie gel staining
was used as a control for protein loading.
Source data are available for this figure.
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mutant mtDNA leaves very little capacity for mtDNA repopulation
and (ii) the m.8993T>G cell line has a tendency to shift heteroplasmy
towards the mutant haplotype (Fig 2D), both masking the efficacy of
mtZFNs and exacerbating the previously stated effect. Further
research is in progress in our laboratory to verify the hypothesis that
a higher initial load of wild-type mtDNA would result in more effi-
cient heteroplasmy shifts of m.8993T>G by mtZFNs. If this assump-
tion is correct, several sequential transfections could produce
complete (or near complete) elimination of mutant mtDNA.
Very recently, an alternative method for specific elimination of
mutant mitochondrial genomes was reported, utilizing mitochondri-
ally targeted TAL-effector nucleases (mitoTALENs) (Bacman et al,
2013). Similar to our experience with mtZFNs, expression of
mitoTALENs led to reductions in deletion and point mutant mtDNA.
Bacman et al also targeted CD; however, a different point mutation
(m.14459G>A) was eliminated in their study. At this stage in the
development of both methodologies, it is not clear which, if either,
solution provides an answer to the current problem of therapeutic
manipulation of mitochondrial heteroplasmy. With advancements
in the field of engineered nuclease technology aimed at minimizing
the risk of use in vivo, or even moving into early-phase clinical trials
(Palpant & Dudzinski, 2013), our work and the results obtained for
mitoTALENs should encourage further experiments in animal mod-
els to ascertain safe use and efficacy. However, prior to this, several
important issues and challenges must be addressed, namely under-
standing the relative specificity of each designer nuclease platform
and harnessing efficient methods for delivering these nucleases in
vivo (Gaj et al, 2013). The considerable size of TALEN assemblies
may also become particularly important in the context of construct
packaging into size-restricted vectors such as the recombinant
adeno-associated virus (AAV), which has already been shown to
accommodate and deliver ZFN constructs (Ellis et al, 2013). This issue
might suggest that the development of new systems for mitoTALEN
delivery will be a critical hurdle to leap in future research.
Our success in delivering ZFNs to mitochondria, altering the ratio
of desired haplotypes also points the way to future applications for
genetic manipulation of mtDNA in basic research. Achieving this
end is of great importance to the entire mitochondrial research com-
munity, as we are currently unable to deliver exogenous nucleic
acids to mitochondria, obstructing all approaches towards engineer-
ing mammalian mtDNA in living cells (Lightowlers, 2011).
Materials and Methods
Transfection and cell culture
Wild-type HOS 143B cells and cybrid HOS 143B cells (Porteous et al,
1998) were maintained in DMEM supplemented with 4.5 g/L
D-glucose, 2 mM l-glutamine, 1 mM sodium pyruvate and 10% FCS
in standard human cell culture conditions. Cultures of CD cybrid cells
were additionally supplemented with 50 lg/ml uridine. Plasmids
containing either NARPd(+), COMPa() R8-n(+) or R13-n() and
empty vectors were linearized and delivered to cells in culture using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. Cells expressing stably integrated vectors and transgenes
were sequentially selected by supplementing standard culture media
with 1 mg/ml neomycin and 4 lg/ml blasticidin for 18 days each.
Cell fractionation
Cell fractionation was performed as described in (Minczuk et al,
2011) without the sucrose gradient step.
Immunodetection of proteins
The localization of proteins by immunofluorescence in fixed HOS
143B cells was performed as described previously (Minczuk, 2010).
The following antibodies were used: rabbit anti-TOM20 (Santa
Cruz), Alexa Fluor 488 anti-rabbit mouse anti-FLAG (Sigma, F1804,
1:200), Alexa Fluor 594 anti-mouse (Life Technologies, A11006,
1:200), rat anti-HA (Roche, 11867431001, 1:200), Alexa Fluor 594
anti-rat (Life Technologies, A11001, 1:200). Immunofluorescence
images were captured using a Nikon N-SIM confocal microscope.
Western blotting analysis was performed as previously (Minczuk
et al, 2011), and membranes were probed with the following pri-
mary antibodies: anti-FLAG and anti-HA as above, mouse anti-OX-
PHOS cocktail (Mitosciences, MS601, 1:300), mouse anti-TOM22
(Abcam, ab10436, 1:5000), mouse anti-b-actin (Sigma, A2228,
1:100,000), rabbit anti-SSB1 (kindly donated by Prof. D. Kang,
1:4000), rabbit anti-histone H4 (Abcam, ab10158; 1:5000). Second-
ary antibodies used were HRP-conjugated goat antibodies to rabbit
(Promega, W401B; 1:2000), mouse (Promega, W402B, 1:2000) and
rat (Santa Cruz, SC2065, 1:1000).
Last cycle hot RFLP
Total cellular DNA was isolated using a DNeasy Blood and Tissue
kit (Qiagen) according to the manufacturer’s instructions. Approxi-
mately 200 ng DNA was used as template for a 15-cycle cold PCR
amplification using KOD polymerase (TaKaRa). A final cycle of PCR
amplification was then performed following the addition of 2 mM
32P-adCTP and the resulting products were purified using a PCR
Purification kit (Qiagen) according to the manufacturer’s instruc-
tions. Purified PCR products were then digested with 20 U SmaI
according to the manufacturer’s instructions and resolved on 1%
agarose gel at 80 V for 1 h. Gels were dried onto DE81 paper
(Whatman) and exposed to a storage phosphor screen for 12 h
before imaging with a Typhoon 9410 scanner and processing with
ImageQuant software (GE Healthcare). Primer sequences were as
follows:
mt. 8339-9334: 50 CCACCCAACAATGACTAATC 30
50 GTATGAGGAGCGTTATGGAG 30
Southern blotting
Total cellular DNA was isolated using a DNeasy Blood and Tissue
kit (Qiagen) according to the manufacturer’s instructions. Approxi-
mately 2.5 lg DNA was digested with 20 U BamHI (New England
Biolabs), and digest fragments were separated on 0.6% agarose gel
for approximately 20 h at room temperature. Gels were blotted onto
nylon membranes (GE Healthcare) and probed with a 32P-radiola-
belled probes in hybridization buffer (7% SDS, 0.5 M sodium phos-
phate buffer, pH 7.4) for 18 h at 65°C. Membranes were washed
three times in 1× SSC with 0.1% SDS and exposed to a storage
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phosphor screen for 24–96 h before imaging with a Typhoon 9410
scanner and processing with ImageQuant software (GE Healthcare).
Probe primer sequences were as follows:
mt. 14986-15607: 50 CTACCTTCACGCCAATGG 30
50 CGATCCGTCCCTAACAAA 30
mt. 10202-10806: 50 CGTCCCTTTCTCCATAAAATTC 30
50 TTGGAAAGTCATGTCAGTGGTAG 30
18S rDNA: 50 GTTGGTGGAGCGATTTGTCT 30
50 GGCCTCACTAAACCATCCAA 30
Extracellular flux analysis
Extracellular flux analysis of OXPHOS function was performed as
described previously (Rorbach et al, 2012), with the details pro-
vided in the Supplementary Materials and Methods.
Other methods
Design and in vitro testing of ZFPs, generation of mtZFN and two-
dimensional agarose gel electrophoresis are presented in the Supple-
mentary Materials and Methods.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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